alexa Progress in the Control of Hepatitis B Virus Infection among Children in Indonesia | Open Access Journals
ISSN: 2157-7560
Journal of Vaccines & Vaccination
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Progress in the Control of Hepatitis B Virus Infection among Children in Indonesia

Takako Utsumi1,2*, Maria I Lusida1, Yoshihiko Yano2, Priyo B Purwono1, Mochamad Amin1, Soetjipto1,
Hak Hotta2 and Yoshitake Hayashi2
1Indonesia-Japan Collaborative Research Center for Emerging and Re-emerging Infectious Diseases, Institute of Tropical Disease, Airlangga University, Surabaya, Indonesia
2Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan
Corresponding Author : Utsumi T
Center for Infectious Diseases
Kobe University Graduate School of Medicine, Kobe, Japan
Tel: +62-31-594-0917
E-mail: [email protected]
Received July 02, 2014; Accepted August 21, 2014; Published August 25, 2014
Citation: Utsumi T, Lusida MI, Yano Y, Purwono PB, Amin M, et al. (2014) Progress in the Control of Hepatitis B Virus Infection among Children in Indonesia. J Vaccines Vaccin 5:247. doi:10.4172/2157-7560.1000247
Copyright: © 2014 Utsumi T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Vaccines & Vaccination

Abstract

Indonesia introduced a universal vaccination program for the hepatitis B virus (HBV) in 1997; however, the longterm efficacy of the HBV vaccination has not yet been established among children. We conducted serological and genetic surveys among children in East Java, Indonesia to assess the progress of the national immunization program. A total of 185 pre-school children aged 1-5 years old born between 2006 and 2011 were enrolled in this study. A total of 150 children (81.1%) were completely vaccinated, and the birth dose coverage within 7 days after birth was 74%. None of the children were positive for the hepatitis B surface antigen (HBsAg), while 4 children were infected with occult HBV. The prevalence of anti-HBs antibody positive was only 26.5%, and positive prevalence and titer of anti-HBs decreased with age. The universal HB vaccination is considered effective in preventing HBV infection in children in this study site, while the protective rate remains insufficient. An effective strategy needs to be developed in order to detect all vaccination failure cases. To achieve complete protection, it would be necessary to consider an appropriate time for the first dose and booster dose.

Abstract

Indonesia introduced a universal vaccination program for the hepatitis B virus (HBV) in 1997; however, the long-term efficacy of the HBV vaccination has not yet been established among children. We conducted serological and genetic surveys among children in East Java, Indonesia to assess the progress of the national immunization program. A total of 185 pre-school children aged 1-5 years old born between 2006 and 2011 were enrolled in this study. A total of 150 children (81.1%) were completely vaccinated, and the birth dose coverage within 7 days after birth was 74%. None of the children were positive for the hepatitis B surface antigen (HBsAg), while 4 children were infected with occult HBV. The prevalence of anti-HBs antibody positive was only 26.5%, and positive prevalence and titer of anti-HBs decreased with age. The universal HB vaccination is considered effective in preventing HBV infection in children in this study site, while the protective rate remains insufficient. An effective strategy needs to be developed in order to detect all vaccination failure cases. To achieve complete protection, it would be necessary to consider an appropriate time for the first dose and booster dose.
 
Keywords

Hepatitis B virus; Pre-school children; Universal vaccination; Indonesia
 
Introduction

The endemicity of hepatitis B virus (HBV) infection was previously reported to be moderate to high in Indonesia [1]. HBV infection is generally acquired during the first five years of life in countries with a high prevalence of chronic HBV infection [2]. Unless vaccinated at birth, the majority of children born to infected mothers become chronically infected [3].

A safe and effective vaccine against HBV infection has been available since 1982, and was recommended by the World Health Organization (WHO) for administration to all infants from 1992. Administration of the hepatitis B (HB) vaccine soon after birth, preferably within 24 hours, is crucial to prevent vertical transmission, and failure to administer this vaccine in a timely manner has been shown to reduce the impact of immunization [4,5]. A total of 179 countries now routinely vaccinate children against HBV and an elimination target has been set at less than 1% infection prevalence in pre-school children in endemic areas [6,7].

However, previous studies have demonstrated difficulties in reaching mothers and their newborn infants around the time of birth in developing countries in which a significant proportion of births occur at home, especially in locations far from the health facility [1,4,8].

The HB universal vaccination was introduced in Indonesia in 1997, with the Indonesian government attempting to ensure that every newborn is vaccinated against HBV infection during the first 7 days of life. The Uniject device, a pre-filled, single use injection device that can be used instead of a traditional syringe and needle, was shown to be crucially important to the HB universal vaccination program in Indonesia [4,9,10]. However, the prevalence of HBV infection among children after implementation of the vaccination program has yet to be determined. We conducted serological and genetic surveys among pre-school children in the community of East Java.
 
Materials and Methods

Study population

Blood samples were collected from a total of 194 pre-school children aged 1-5 years old born between 2006 and 2011 who were admitted to the health program for pre-school children in Posyandu (a satellite health center that delivers vaccinations and nutrition) in the East Perak area (population; 72,744), East Java in January 2011. Of the 194 children, 185 (mean age 3.6 ± 1.2 years old, 106 boys and 79 girls) with vaccination cards were enrolled in this study. The vaccination histories of these children were obtained from vaccination cards provided by the local health office. A questionnaire including demographic data and the place of birth was given to the guardians of the children. Written informed consent was provided by the guardians and a research permit was also obtained from the local health office. The study protocol was reviewed and approved by the Ethics Committees of Kobe University in Japan and Airlangga University in Indonesia.
 
Universal HB vaccination in Indonesia

The HB vaccination schedule in Indonesia is shown in Table 1. Indonesia is currently the only country with a national policy of using the HB vaccine in the Uniject presentation, including outside the cold chain. Uniject has been used as a birth dose, and is recommended within 7 days of birth in Indonesia (1,10). Uniject and the DTP-HB combination vaccine are manufactured by Biofarma in Indonesia, and these recombinant vaccines contain a non-infectious hepatitis B viral antigen that is produced in yeast cells using recombinant DNA technology. In the study sites, Uniject and the DTP-HB combination vaccine have been employed for children since 2005.
 
Serological markers of HBV infection

Serum samples were tested for HBsAg by Reversed Passive Hemagglutination (R-PHA) (Mycell II HBsAg; Institute of Immunology, Tokyo, Japan) and also the anti-HBs antibody by Enzyme-linked immunosorbent assay (ELISA) (Hepalisa anti-HBsAg: Indec Diagnostics, Jakarta, Indonesia). The cut-off level of the anti-HBs antibody was decided as 10 mIU/ml. To differentiate vaccine-induced antibodies from naturally acquired antibodies in children, the prevalence of the antibody to the hepatitis B core antigen (anti-HBc antibody) was assessed by PHA (Mycell anti-rHBc; Institute of Immunology, Tokyo, Japan).
 
Sequence analysis in the a determinant region in HBsAg-negative children

After being assayed for the HBV serological status, 54 serum samples that were negative for HBsAg but positive for either anti-HBs or anti-HBc were subjected to HBV genetic analysis to identify surface antigen variants. After serological testing, serum samples were stored at -20°C until genetic testing. DNA was extracted from 100 μl of serum samples using a DNA extractor kit (QIAamp DNA Blood Mini Kit; QIAGEN, Tokyo, Japan). The presence of HBV DNA was assayed by single PCR using the primers HBSF2; 5’-CTTCATCCTGCTGCTATGCCT-3’ and HBSR2; 5’-AAAGCCCAGGATGATGGGAT-3’ corresponding to the determinant region, which is involved in antigenicity, as previously described [11]. Amplified fragments were directly sequenced using the Big Dye Deoxy Terminator cycle sequencing kit with an ABI PRISM 310 genetic analyzer (Applied Biosystems, Foster City, CA). The HBV nucleotide sequences of the S gene were translated to amino acid (aa) sequences and aligned with reference sequences. The aa substitutions in the a determinant region (aa124-147) of the S genes were then analyzed.
 
Confirmation of HBsAg in HBV DNA-positive children

To minimize the possibility of false-negative results for HBsAg, an enzyme-linked immunosorbent assay (ELISA) (Hepalisa HBsAg: Indec Diagnostics, Jakarta, Indonesia) and an immunochromatography method based on the principal of an enzyme immunoassay (EIA) (Espline HBsAg; Fuji Rebio, Tokyo, Japan), were used for samples that were HBsAg negative by RPHA, but HBV DNA positive by PCR.

HBV genotyping. HBV genotypes/subgenotypes were determined using a phylogenetic tree of the S region. Reference sequences were retrieved from the DNA DataBank of the Japan/European Molecular Biology Laboratory/GenBank database. Alignments were performed using CLUSTAL X software, a phylogenetic tree was constructed using the neighbor-joining method, and bootstrap resampling was performed 1,000 times. Analyses were conducted using the Molecular Evolutionary Genetics Analysis (MEGA) software program.
 
Statistical analysis

Significance was evaluated by the chi-square test or Fisher’s exact test for categorical variables. The independent t-test was used for continuous variables, as appropriate. A P value<0.05 was considered significant.
 
Results

Coverage and timing of the birth dose HB vaccine in children

Of the 185 children with vaccination data, 166 (89.7%) were vaccinated by the first dose HB vaccine (Uniject). The timing of the birth dose HB vaccine by days after birth in the present study was shown in Figure 1. Of these 166 children, 53 (31.9%) and 63 (38.0%) were vaccinated within 24 hours and 1-6 days after birth, respectively. Overall, 116 of 166 children (69.9%) were administered the birth dose within 7 days after birth, whereas the remaining 50 (30.1%) children were administered the first dose one week or later after birth. A total of 150 children (81.1%) completed the HB vaccination program scheduled by the Indonesian government (a birth dose HB vaccine by Uniject and 3 DTP/HB combination vaccines). Of the 150 children who completed the HB vaccination program, the coverage of the birth dose vaccine within 24 hours, 1-6 days, and 7 days or more after birth were 34.0% (51/150), 40.0% (60/150), and 26.0% (39/150), respectively. In total, coverage within 7 days after birth was 74% (111/150).
 
Birthplace and first dose coverage

Of the 157 children with known birthplaces, 92 (58.6%) were born in a hospital, 56 (35.7%) were born outside of a hospital with the help of a skilled birth attendant (SBA), and 9 (5.7%) were born at home without a SBA. The birth dose coverage with timelines was summarized depending on the birthplace, as shown in Table 2. No significant difference was observed in the birth dose coverage within 24 hours of being born between birthplaces. However, the birth dose coverage within 7 days at home without a SBA was significantly lower (55.6%) than that at a health facility, at home with a SBA (92.9%, p=0.009), and at a hospital (87.0%, p=0.03).
 
Serological status among children

Serological tests for HBV infection revealed that 49 (26.5%) and 6 (3.2%) out of 185 children were positive for anti-HBs and anti-HBc, respectively. None of children were positive for HBsAg. The positivity of anti-HBs gradually decreased from 60.0% at 1 year of age to 12.0% at 5 years of age. The mean titer of anti-HBs among children gradually decreased from 462.0 mIU/ml at 1 year of age to 180.5 mIU/ml at 5 years of age (Figure 2). Forty-seven (95.9%) of the 49 children who were anti-HBs positive were negative for the anti-HBc antibody, which suggested successful immunization by the HB vaccine.
 
Detection of HBV-DNA and mutations in the S gene

HBV-DNA was detected in 4 (7.4%) out of 54 children who were HBsAg negative but positive for either anti-HBs or anti-HBc, which indicated occult HBV infection. All 4 children were completely vaccinated by the HB vaccine. AA substitutions in the determinant region were detected in 3 children, as shown in Table 3. The HBV strains of children PTA142 and PTA148 had 3 substitutions, T126I, M133L, and T143S, and the PTA26 strain had the substitution Q129H. PTA198 was a wild type strain. Three (PTA26, PTA 142, and PTA198) of the 4 children were positive for anti-HBs, and vaccinated first dose within 7 days as scheduled (Table 3). The status of the four children with undetectable HBsAg was suggested as follows: PTA26 and PTA142 had vaccine escape mutants; PTA148 was naturally infected with vaccine escape mutants, and PTA198 had recovered from wild-type HBV infection. The HBV genotypes were successfully determined for 3 children. HBV genotype B (HBV/B) was identified in one child and HBV/C was identified in 2 children, as shown in Figure 3.
 
Discussion

The primary objectives of this study were to assess the status of HBV infection among pre-school children and profile the vaccination practice in East Perak area. Our study revealed that none of the 1-5 year old children who participated in this study were infected by HBV. This result is markedly lower than that among pre-school children in another area of Indonesia (Purwono et al, unpublished data). Since the prevalence of HBsAg among the general population in this area was 6.7% [12], children in this study were considered to be protected from either perinatal or horizontal transmission. However, these results cannot confirm a decrease in the prevalence of HBsAg because it has never been tested in pre-school children in this study site. Moreover, the overall positive rate of anti-HBs alone, which means immunized well due to the HB vaccine, was lower in this study population than those in other countries [8,13].

Vaccination coverage (defined as the percentage of children administered the complete HB vaccine in the present study; 1 Uniject and 3 DTP-HB combination) was higher (81%) in this study than in the 2013 WHO/UNICEF report in which 63% HB vaccination coverage was achieved in all of Indonesia [14]. The prevalence of HBsAg was zero among pre-school children in the present study, which indicated that the local health office in this study site may have achieved the HBV elimination target of less than 1% infection in pre-school children. On the other hand, the prevalence of HBV in school children aged 6-13 years old was 2.8% in the same area (Utsumi et al. unpublished data), which indicated that the risk of being infected with HBV was still present if children were not continually protected, especially in endemic areas including Indonesia.

The seropositive rate of anti-HBs at 1 year of age after completion of the HB vaccination program in the present study was inconsistent with the almost 100% reported in a previous study [15]. We suggested two possible reasons for the lower immune response in this study: a delay in administrating the birth dose vaccine and the loss of protective antibodies to HBV infection [16]. The birth dose coverage within 7 days after birth was 70% in the present study. Although enough data is not available on the timing of the birth dose in other areas in Indonesia, except for Southeast Sulawesi (39%) in which 97% of deliveries occur at home [1], the local health office in this study site attempted to reach recommended targets set by the Indonesian government to administer the first dose within 7 days after birth. If we consider the birth dose coverage within 24 hours, a delayed birth dose may play a role in the low response of 30%; however, children were not infected with HBV at least by 5 years of age. On the other hand, occult HBV infection (HBsAg negative but HBV DNA positive) was found in 4 children in this study, even though 3 of them were vaccinated first dose within 7 days after birth (one child within 24 hours). This suggests the importance to recognize the risk factors for vertical transmission during pregnancy [17].

The titer of the anti-HBs antibody gradually decreased with age in this study. A previous study revealed that the positivity of protective anti-HBs gradually decreased with age and reached undetectable levels by 12 years of age. Due to the loss of protection, these anti-HBs-negative children may be at a higher risk of HBV infection [18]. Moreover, Biofarma Indonesia reported that a booster dose is required every 5 years after the primary course of vaccination [19]. Therefore, the continuous monitoring of protection against HBV in school age children is needed in order to confirm the necessity of a booster dose; however, booster doses against HBV remain controversial because of the anamnestic response [20,21].

The WHO recommends that all infants should receive their birth dose of the HB vaccine as soon as possible after birth, preferably within 24 hours [22]. However, in the present study, the difference in the protection rates with hepatitis B vaccine between the vaccination times, i.e., within 24 hours and 7 days after birth, is unclear because of the small sample size. In the present study, children delivered at home without a SBA had a significantly lower chance of being administered the birth dose vaccine than those delivered in a health facility or hospital. Although this study site is a small town in the second largest city (population; 3 million) in Indonesia and is more accessible to health facilities than other remote areas, 5.7% of newborn babies were born at home without a SBA. A timely birth dose for a baby delivered at home without a SBA requires the mother to visit a health facility within 7 days of delivery, which is possible in this study site. Improving facility delivery rates may help improve birth dose HB vaccination coverage by providing an opportunity to educate mothers of the need for vaccines [8].

Antibodies to HBsAg are mainly targeted to bind the amino acid hydrophilic region, referred to as the determinant of HBsAg. This provides protection against infection from all HBV genotypes and is responsible for the broad immunity afforded by the hepatitis vaccination [23,24]. Two escape mutants were identified in this study. The emergence of HBV S-gene mutants that may be able to escape the vaccine-induced response has been suggested. However, the overall impact of such mutants currently remains low, and they do not pose a public health threat or the need to modify established hepatitis B vaccination programs [25-27]. A comparison with previous studies performed in other countries showed that the most common escape mutant G145R is currently rare in Indonesia [23,25].

Breakthrough infections in these immunized infants have been attributed to the timing of the vaccinations, especially the birth dose of the HB vaccine [13]. Other identified causes include inadequate vaccine storage, incomplete dosage, or improper administration [1,24]. Immune responses to vaccinations and the outcomes of HBV infection are also known to be influenced by the type of HLA allele [28]. Geographical and ethnic differences may also play a role [8,24].

In conclusion, the universal HB vaccination effectively prevented the transmission of HBV in children at least until 5 years of age in the present study; however, the protective rate remains insufficient. Anti-HBs-negative children may be at a higher risk of HBV infection in HBV endemic countries including Indonesia. An effective strategy needs to be developed to detect all vaccination failure cases in order to achieve the complete control of HBV infection. To achieve complete protection, it would be necessary to consider an appropriate time for the first dose and booster dose.
 
Acknowledgments

This study was supported by a Grant-in-Aid from the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID) program from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Japan. We would like to thank the health center at East Perak for sample collection.
 
References


Tables and Figures at a glance

 

Table icon Table icon Table icon
Table 1 Table 2 Table 3

 

Figures at a glance

 

Figure Figure Figure
Figure 1 Figure 2 Figure 3
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 11615
  • [From(publication date):
    October-2014 - Jun 28, 2017]
  • Breakdown by view type
  • HTML page views : 7857
  • PDF downloads :3758
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords